SACUBITRIL/VALSARTAN USE IN A REAL WORLD EXPERIENCE: DATA FROM A LARGE SINGLE-CENTER POPULATION OF HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION

被引：0
|
作者：
Mapelli, M.
Salvioni, E.
Mattavelli, I.
Sassi, V.
Gugliandolo, P.
Mantegazza, V.
Volpato, V.
Vignati, C.
De Martino, F.
Paolillo, S.
Contini, M.
Apostolo, A.
Magini, A.
Palermo, P.
Agostoni, P.
机构：
[1] IRCCS, Ctr Cardiol Monzino, Milan, Italy
[2] Univ Federico II, Naples, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2020年 / 22卷 / 0G期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P361
引用
收藏
页码：G188 / G189
页数：2
相关论文
共 50 条
  • [41] DIASTOLIC FUNCTION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED BY SACUBITRIL/VALSARTAN
    Lamaida, N.
    Cerciello, A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)
  • [42] Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction
    Barman, Hasan Ali
    Tanyolac, Selim
    Dogan, Omer
    Bal, Erdem
    Atici, Adem
    Ozyildirim, Serhan
    Yigit, Zerrin
    CLINICAL DRUG INVESTIGATION, 2022, 42 (06) : 533 - 540
  • [43] TOLERABILITY OF SACUBITRIL-VALSARTAN IN PATIENTS WITH CANCER AND HEART FAILURE WITH REDUCED EJECTION FRACTION
    Yarrabothula, Akshitha R.
    Alsheikh-Kassim, Mohammad
    Amatullah, Atia
    Fossas, Jose
    Salman, Justin
    Seal, Zachary
    Lin, Heather
    Irizarry-Caro
    Wanna, Charles
    Miller, Chase
    Fatakdawala, Mariya
    Palaskas, Nicolas L.
    Deswal, Anita
    Koutroumpakis, Efstratios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2325 - 2325
  • [44] Clinical benefit of sacubitril-valsartan in patients with heart failure with reduced ejection fraction
    Spinoni, Enrico Guido
    Lio, Veronica
    Degiovanni, Anna
    Erbetta, Riccardo
    Marino, Paolo
    Patti, Giuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N101 - N101
  • [45] Real world experience with sacubitril/valsartan in heart failure
    Lim, E. L. S.
    Abdullah, E. L.
    Loh, L. C. W.
    Chong, P. F.
    Sia, H. P.
    Sothivadivel, S.
    Lee, J. L.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 417
  • [46] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
    Takigami, Yu
    Ishii, Shunsuke
    Eda, Yuko
    Yazaki, Mayu
    Fujita, Teppei
    Iida, Yuichiro
    Ikeda, Yuki
    Nabeta, Takeru
    Oikawa, Jun
    Koitabashi, Toshimi
    Ako, Junya
    HEART AND VESSELS, 2023, 38 (11) : 1337 - 1343
  • [47] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
    Yu Takigami
    Shunsuke Ishii
    Yuko Eda
    Mayu Yazaki
    Teppei Fujita
    Yuichiro Iida
    Yuki Ikeda
    Takeru Nabeta
    Jun Oikawa
    Toshimi Koitabashi
    Junya Ako
    Heart and Vessels, 2023, 38 : 1337 - 1343
  • [48] Novel pharmacological options in patients with heart failure with reduced ejection fraction: sacubitril-valsartan vs ferric carboxymaltose in a real world population.
    Piccoli, A.
    Benini, A. C.
    Tonelli, J.
    Zanolla, L.
    Benini, A.
    Ribichini, F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 222 - 223
  • [49] Use of sacubitril/valsartan in patients with heart failure: evidence from the real world
    Valladales-Restrepo, Luis Fernando
    Sanchez-Ramirez, Nicolas
    Usma-Valencia, Andres Felipe
    Velasquez-Quirama, Santiago
    Henao-Martinez, Manuela
    Castro-Rodriguez, Jorge Alejandro
    Gaviria-Mendoza, Andres
    Machado-Duque, Manuel Enrique
    Machado-Alba, Jorge Enrique
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2211 - 2219
  • [50] Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry
    Savarese, G.
    Hage, C.
    Benson, L.
    Schrage, B.
    Thorvaldsen, T.
    Lundberg, A.
    Fudim, M.
    Linde, C.
    Dahlstrom, U.
    Rosano, G. M. C.
    Lund, L. H.
    JOURNAL OF INTERNAL MEDICINE, 2021, 289 (03) : 369 - 384
12345